

Member FINRA/SIPC

Toll-Free: 561-391-5555 ♦ www.DawsonJames.com ♦ 1 North Federal Highway - Suite 500 ♦ Boca Raton, FL 33432

CytoSorbents Corporation (NASDAQ/CTSO)

June 9, 2020

BUY: Picks Up a \$3M Contract for HemoDefend

CytoSorbents announced that the Defense Health Agency Small Business Technology Transfer (STTR) has awarded a Phase 3 contract, valued at up to \$2.8 over 2 years, to advance its HemoDefend-BGA plasma and whole blood absorber to human clinical trials.

Jason H. Kolbert
 Head of Healthcare Research
 646-465-6891
 jkolbert@dawsonjames.com

Current Price **\$9.08**
 Price Target **\$17.00**

HemoDefend. There has been an ongoing controversy on whether there is a difference between "old" blood and "new" blood, or blood that has been stored for some time in a refrigerated compartment versus blood that has been freshly donated by a person. Although current studies show contradicting results (independent studies were highly varied in approach), it is undisputed that biological changes occur during RBC storage, although it is unknown if they are beneficial/harmless or detrimental changes. Whether or not aged blood is bad, HemoDefend is still advantageous when storing donated blood. Not only will it keep donated blood fresh and extend the shelf-life of blood, but it will also remove the many contaminants that may be present in donated blood, or from the changes RBCs undergo while in storage. This is to minimize the current 1-5% risk chance patients have of developing a transfusion reaction, which could be as mild as a fever to as severe as death.

The HemoDefend technology can be implemented in two ways; as an in-line filter between the blood bag and the patient during transfusion, or in an approach called "Beads in a Bag." Beads in a Bag is CytoSorbents' innovative, patent-pending technology that will purify blood during the entire refrigerated storage period. CytoSorbents' biocompatible beads are perfect for this use for several reasons: the beads can have extended contact with blood without causing damage to the RBCs, they are neutrally buoyant and will suspend in blood so that the blood storage bag does not need to be mixed, and during transfusion, an integrated filter will keep the beads in the bag. HemoDefend won't require any extra machine, electricity, energy source, or any other manipulation to be used, so it won't cost much to possibly save a life.

Valuation. We use a series of therapeutic models across the various indications and geographies and project product revenues for the company out to the year 2030. In our U.S. therapeutic models, we apply a 30% risk cut (70% success probability) that both U.S. approvals and our market share forecasts can be realized. For us, valuation becomes an interesting question when we discuss the appropriate "r" risk-rate to use in our three model metrics, free cash flow to the firm (FCFF), Discounted EPS and Sum-Of-The-Parts (SOP) models, which are equal-weighted, averaged and rounded to the nearest whole number. Typically for early-stage companies with no revenues, we use 30%, and for companies with established products and revenues, we use a lower 15%. CytoSorbents arguably is somewhere in the middle, as products are approved and selling in Europe but not yet in the U.S. If we select a conservative 30%, we drive a \$9.00 price target. If we select a more aggressive 15%, we arrive at a \$28.00 target. If we select a mid-point (22.5%), we derive a \$17.00 target.


Risk. Market risks, Regulatory risks, Financial risks, and Commercialization risks.

Estimates	F2019A	F2020E	F2021E
Expenses (\$000s)	\$ 43,924	\$ 48,085	\$ 60,071
1Q March	\$ 9,475	\$ 11,186	\$ 13,816
2Q June	\$ 9,862	\$ 11,501	\$ 14,417
3Q September	\$ 11,723	\$ 12,459	\$ 15,618
4Q December	\$ 12,864	\$ 12,939	\$ 16,219

	F2019A	F2020E	F2021E
EPS (diluted)	\$ (0.62)	\$ (0.39)	\$ 0.24
1Q March	\$ (0.15)	\$ (0.10)	\$ 0.06
2Q June	\$ (0.11)	\$ (0.09)	\$ 0.06
3Q September	\$ (0.21)	\$ (0.10)	\$ 0.06
4Q December	\$ (0.14)	\$ (0.10)	\$ 0.07

EBITDA/Share	(\$0.63)	(\$0.41)	\$0.27
EV/EBITDA (x)	0.0	0.0	0.0

Stock Data		
52-Week Range	\$3.49	\$11.24
Shares Outstanding (mil.)	36.2	
Market Capitalization (mil.)	\$329	
Enterprise Value (mil.)	\$309	
Debt to Capital	0%	
Book Value/Share	\$0.35	
Price/Book	36.7	
Average Three Months Trading Volume (K)	1,194	
Insider Ownership	13.5%	
Institutional Ownership	27.5%	
Short interest (mil.)	7.3%	
Dividend / Yield	\$0.00/0.0%	



Modeling Assumptions

1. We assume continued steady growth for CytoSorb in the current key EU direct sales countries of Germany, Austria, and Switzerland.
2. We assume a selling price per cartridge of \$1,000 for direct sales and \$600 for distribution sales. We estimate that each patient will require an average of five units (CytoSorb cartridges) for sepsis treatment and three units for cardiac treatment.
3. We conservatively assume that CytoSorb can achieve a ten percent market share of the market in Germany, Austria and Switzerland, and 3% of the market in the rest of the EU by 2030.
4. Our model includes CytoSorb revenues in the U.S. for cardiac surgery and sepsis beginning in 2022 upon commercialization. To these revenues, we apply a 70% probability of success (or 30% risk cut).

Exhibit 1. CytoSorb sepsis EU direct sales (Germany, Austria, and Switzerland)

CytoSorb Direct Sales (Germany, Austria, Switzerland)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EU population	506,327,109	507,441,029	508,557,399	509,676,225	510,797,513	511,921,267	513,047,494	514,176,199	515,307,386	516,441,062	517,577,233	518,715,903	519,857,078
Germany population	81,202,563	81,632,936	82,065,591	82,500,539	82,937,791	83,377,392	83,819,262	84,263,504	84,710,100	85,159,064	85,610,407	86,064,142	86,520,282
Austria population	8,446,189	8,448,723	8,451,257	8,453,793	8,456,329	8,458,866	8,461,404	8,463,942	8,466,481	8,469,021	8,471,562	8,474,103	8,476,646
Switzerland population	8,098,152	8,115,158	8,132,200	8,149,277	8,166,391	8,183,540	8,200,726	8,217,947	8,235,205	8,252,499	8,269,829	8,287,196	8,304,599
Critical care population (Sepsis included)	498,509	500,804	503,110	505,428	507,759	510,101	512,455	514,822	517,200	519,591	521,994	524,410	526,838
Percent of patients with access to hospitals with CytoSorb	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Total patients	249,254,60	250,401,88	251,555,07	252,714,20	253,879,30	255,050,41	256,227,55	257,410,75	258,600,06	259,795,49	260,997,08	262,204,88	263,418,89
Market penetration	1.2%	1.7%	1.8%	2.0%	3.0%	4.0%	5.0%	5.5%	6.0%	6.5%	7.0%	7.5%	8.0%
Total addressable patients	2,991	4,257	4,528	5,054	7,616	10,202	12,811	14,158	15,516	16,887	18,270	19,665	21,074
Estimated units per patient	5	5	5	5	5	5	5	5	5	5	5	5	5
Total filler needed	14,955	21,284	22,640	25,271	38,082	51,010	64,057	70,788	77,580	84,434	91,349	98,327	105,368
Cost of therapy	\$ 1,030	\$ 1,041	\$ 1,051	\$ 1,062	\$ 1,072	\$ 1,083	\$ 1,094	\$ 1,105	\$ 1,116	\$ 1,127	\$ 1,138	\$ 1,149	\$ 1,161
Change in price	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Revenue ('000)	\$ 15,408	\$ 22,148	\$ 23,795	\$ 26,826	\$ 40,829	\$ 55,237	\$ 70,058	\$ 78,194	\$ 86,554	\$ 95,142	\$ 103,964	\$ 113,024	\$ 122,328
Risk factor													
Total revenue ('000)	\$ 15,408	\$ 22,148	\$ 23,795	\$ 26,826	\$ 40,829	\$ 55,237	\$ 70,058	\$ 78,194	\$ 86,554	\$ 95,142	\$ 103,964	\$ 113,024	\$ 122,328

Source: Dawson James estimates

Exhibit 2. CytoSorb sepsis EU sales by distributorship (excluding Germany, Austria, and Switzerland)

CytoSorb Direct Sales (Germany, Austria, Switzerland)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EU population	506,327,109	507,441,029	508,557,399	509,676,225	510,797,513	511,921,267	513,047,494	514,176,199	515,307,386	516,441,062	517,577,233	518,715,903	519,857,078
Germany population	81,202,563	81,632,936	82,065,591	82,500,539	82,937,791	83,377,392	83,819,262	84,263,504	84,710,100	85,159,064	85,610,407	86,064,142	86,520,282
Austria population	8,446,189	8,448,723	8,451,257	8,453,793	8,456,329	8,458,866	8,461,404	8,463,942	8,466,481	8,469,021	8,471,562	8,474,103	8,476,646
Switzerland population	8,098,152	8,115,158	8,132,200	8,149,277	8,166,391	8,183,540	8,200,726	8,217,947	8,235,205	8,252,499	8,269,829	8,287,196	8,304,599
Critical care population (Sepsis included)	498,509	500,804	503,110	505,428	507,759	510,101	512,455	514,822	517,200	519,591	521,994	524,410	526,838
Percent of patients with access to hospitals with CytoSorb	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Total patients	249,254,60	250,401,88	251,555,07	252,714,20	253,879,30	255,050,41	256,227,55	257,410,75	258,600,06	259,795,49	260,997,08	262,204,88	263,418,89
Market penetration	1.2%	1.7%	1.8%	2.0%	3.0%	4.0%	5.0%	5.5%	6.0%	6.5%	7.0%	7.5%	8.0%
Total addressable patients	2,991	4,257	4,528	5,054	7,616	10,202	12,811	14,158	15,516	16,887	18,270	19,665	21,074
Estimated units per patient	5	5	5	5	5	5	5	5	5	5	5	5	5
Total filler needed	14,955	21,284	22,640	25,271	38,082	51,010	64,057	70,788	77,580	84,434	91,349	98,327	105,368
Cost of therapy	\$ 1,030	\$ 1,041	\$ 1,051	\$ 1,062	\$ 1,072	\$ 1,083	\$ 1,094	\$ 1,105	\$ 1,116	\$ 1,127	\$ 1,138	\$ 1,149	\$ 1,161
Change in price	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Revenue ('000)	\$ 15,408	\$ 22,148	\$ 23,795	\$ 26,826	\$ 40,829	\$ 55,237	\$ 70,058	\$ 78,194	\$ 86,554	\$ 95,142	\$ 103,964	\$ 113,024	\$ 122,328
Risk factor													
Total revenue ('000)	\$ 15,408	\$ 22,148	\$ 23,795	\$ 26,826	\$ 40,829	\$ 55,237	\$ 70,058	\$ 78,194	\$ 86,554	\$ 95,142	\$ 103,964	\$ 113,024	\$ 122,328

Source: Dawson James estimates

Exhibit 3. CytoSorb U.S. sales for cardiac surgery

CytoSorb Cardiac Surgery US	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
US population	327,296,502	329,587,577	331,894,690	334,217,953	336,557,479	338,913,381	341,285,775	343,674,775	346,080,499	348,503,062	350,942,583	353,399,182	355,872,976
Cardiac surgery	1,009,027	1,012,054	1,015,090	1,018,136	1,021,190	1,024,254	1,027,326	1,030,408	1,033,499	1,036,600	1,039,710	1,042,829	1,045,957
Market penetration	0.09%	0.1%	0.2%	0.3%	0.4%	0.5%	0.6%	0.7%	0.8%	0.9%	1.0%	1.1%	1.2%
Total addressable patients	3	3	3	3	3	3	3	3	3	3	3	3	3
Estimated units per patient	3	3	3	3	3	3	3	3	3	3	3	3	3
Total filler needed	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218	9,218
Cost of therapy	\$ 2,500	\$ 2,513	\$ 2,525	\$ 2,537	\$ 2,549	\$ 2,561	\$ 2,573	\$ 2,585	\$ 2,597	\$ 2,609	\$ 2,621	\$ 2,633	\$ 2,645
Change in price	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Revenue ('000)	\$ -	\$ -	\$ -	\$ 23,277	\$ 31,284	\$ 39,419	\$ 47,554	\$ 55,689	\$ 63,824	\$ 71,959	\$ 80,094	\$ 88,229	\$ 96,364
Risk factor				30%	30%	30%	30%	30%	30%	30%	30%	30%	30%
Total revenue ('000)	\$ -	\$ -	\$ -	\$ 16,294	\$ 21,899	\$ 27,593	\$ 33,287	\$ 39,022	\$ 44,767	\$ 50,512	\$ 56,257	\$ 62,002	\$ 67,747

Source: Dawson James estimates

Exhibit 4. CytoSorb EU sales for cardiac surgery

CytoSorb Cardiac Surgery EU	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EU population	506,327,109	507,441,029	508,557,399	509,676,225	510,797,513	511,921,267	513,047,494	514,176,199	515,307,386	516,441,062	517,577,233	518,715,903	519,857,078
Cardiac surgery	1,509,018	1,512,036	1,515,060	1,518,090	1,521,125	1,524,169	1,527,217	1,530,271	1,533,332	1,536,399	1,539,471	1,542,550	1,545,635
Market penetration	0.09%	0.1%	0.2%	0.3%	0.4%	0.5%	0.6%	0.7%	0.8%	0.9%	1.0%	1.1%	1.2%
Total addressable patients	1,358	1,512	2,273	4,554	6,085	7,621	9,163	10,712	12,261	13,810	15,359	16,908	18,457
Estimated units per patient	3	3	3	3	3	3	3	3	3	3	3	3	3
Total filler needed	4,074	4,536	6,818	13,663	18,254	22,845	27,436	32,027	36,618	41,209	45,800	50,391	54,982
Cost of therapy	\$ 500	\$ 500	\$ 500	\$ 503	\$ 505	\$ 508	\$ 510	\$ 513	\$ 515	\$ 518	\$ 520	\$ 523	\$ 526
Change in price	0%	0%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Revenue ('000)	\$ 2,037	\$ 2,268	\$ 3,409	\$ 6,866	\$ 9,218	\$ 11,604	\$ 14,022	\$ 16,474	\$ 18,926	\$ 21,378	\$ 23,830	\$ 26,282	\$ 28,734
Risk factor													
Total revenue ('000)	\$ 2,037	\$ 2,268	\$ 3,409	\$ 6,866	\$ 9,218	\$ 11,604	\$ 14,022	\$ 16,474	\$ 18,926	\$ 21,378	\$ 23,830	\$ 26,282	\$ 28,734

Source: Dawson James estimates

Exhibit 5. CytoSorb U.S. sales for sepsis

US population	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
US population	327,296,502	329,587,577	331,894,690	334,217,953	336,557,479	338,913,381	341,285,775	343,674,775	346,080,499	348,503,062	350,942,583	353,399,182	355,872,976
Severe sepsis patients	981,890	988,763	995,684	1,002,624	1,009,672	1,016,740	1,023,857	1,031,024	1,038,241	1,045,509	1,052,829	1,060,198	1,067,619
Market penetration	0.1%	0.2%	0.3%	0.4%	0.5%	0.6%	0.7%	0.8%	0.9%	1.0%	1.1%	1.2%	1.3%
Total addressable patients	1,003	2,019	5,084	10,209	20,420	30,631	40,842	51,053	61,264	71,475	81,686	91,897	102,108
Estimated units per patient	5	5	5	5	5	5	5	5	5	5	5	5	5
Total filler needed	5,013	10,097	25,419	51,045	102,090	153,135	204,180	255,225	306,270	357,315	408,360	459,405	510,450
Cost of therapy	\$ 2,500	\$ 2,525	\$ 2,550	\$ 2,575	\$ 2,600	\$ 2,625	\$ 2,650	\$ 2,675	\$ 2,700	\$ 2,725	\$ 2,750	\$ 2,775	\$ 2,800
Change in price	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Revenue ('000)	\$ 12,533	\$ 25,494	\$ 64,824	\$ 131,860	\$ 263,720	\$ 527,440	\$ 791,160	\$ 1,054,880	\$ 1,318,600	\$ 1,582,320	\$ 1,846,040	\$ 2,109,760	\$ 2,373,480
Risk factor			</										

Valuation. We use a series of therapeutic models across the various indications and geographies and project product revenues for the company out to the year 2030. In our U.S. therapeutic models, we apply a 30% risk cut (70% success probability) that both U.S. approvals and our market share forecasts can be realized. For us, valuation becomes an interesting question when we discuss the appropriate "r" risk-rate to use in our three model metrics, free cash flow to the firm (FCFF), Discounted EPS and Sum-Of-The-Parts (SOP) models, which are equal-weighted, averaged and rounded to the nearest whole number. Typically for early-stage companies with no revenues, we use 30%, and for companies with established products and revenues, we use a lower 15%. CytoSorbents arguably is somewhere in the middle, as products are approved and selling in Europe but not yet in the U.S. If we select a conservative 30%, we drive a \$9.00 price target. If we select a more aggressive 15%, we arrive at a \$28.00 target. If we select a mid-point (22.5%), we derive a \$17.00 target. Given their unique position of approval in Europe, established proof of concept, and a product that works, we select the mid-point of 22.5% and set our target for CytoSorbents at \$17.00.

Exhibit 6. FCFF Model

Average \$	17
Price Target \$	17
Year	2020

DCF Valuation Using FCF (mln):

units ('000)	2018A	2019A	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EBIT	(17,830)	(20,358)	(13,926)	9,301	32,034	83,013	147,875	252,067	315,248	356,152	386,456	405,408	401,536
Tax Rate	0%	5%	8%	10%	12%	15%	18%	21%	24%	28%	33%	33%	33%
EBIT (1-t)	(17,830)	(19,340)	(12,812)	8,371	28,190	70,561	121,257	199,133	239,589	256,429	258,926	271,623	269,029
CapEx	(493)	(698)	(768)	(845)	(929)	(1,022)	(1,124)	(1,237)	(1,361)	(1,497)	(1,646)	(1,811)	(1,992)
Depreciation	391	582	-	-	-	-	-	-	-	-	-	-	-
Change in NWC	-	-	-	-	-	-	-	-	-	-	-	-	-
FCF	(17,932)	(19,457)	(13,580)	7,526	27,261	69,539	120,133	197,896	238,228	254,933	257,279	269,812	267,037
PV of FCF	(26,910)	(23,834)	(13,580)	6,144	18,166	37,828	53,348	71,739	70,498	61,585	50,736	43,435	35,092
Discount Rate	22.5%												
Long Term Growth Rate	1%												
Terminal Cash Flow	1,254,453												
Terminal Value YE2030	164,852												
NPV	599,843												
NPV:Debt	-												
Shares out ('000)	35,420												
NPV Per Share	17												

Source: Dawson James estimates

Exhibit 7. Discounted EPS Model

Current Year	2020
Year of EPS	2030
Earnings Multiple	15
Discount Factor	22.5%
Selected Year EPS	7.60
NPV	14.97

Source: Dawson James estimates

Discount Rate and Earnings Multiple Varies, Year is Constant							
Earnings Multiple	14.97	5%	10%	15%	20%	25%	30%
	0	0.00	0.00	0.00	0.00	0.00	0.00
5	23.31	14.64	9.39	6.13	4.08	2.75	2.75
10	46.63	29.28	18.77	12.27	8.16	5.51	5.51
15	69.94	43.92	28.16	18.40	12.23	8.26	8.26
20	93.26	58.57	37.55	24.53	16.31	11.02	11.02
25	116.57	73.21	46.94	30.67	20.39	13.77	13.77
30	139.89	87.85	56.32	36.80	24.47	16.53	16.53
35	163.20	102.49	65.71	42.93	28.54	19.28	19.28

Source: Dawson James estimates

Exhibit 8. Sum of the Parts Model

CytoSorbents	LT Gr	Discount Rate	Yrs to Mkt	% Success	Peak Sales (MMs)	Term Val
CytoSorb - Sepsis Direct Sales(EU)	1%	22.5%	0	70%	\$151	\$701
NPV						\$8
CytoSorb - Sepsis Distributor (EU)	1%	22.5%	0	70%	\$88	\$408
NPV						\$4
CytoSorb (Cardiac surgery US)	1%	22.5%	2	50%	\$68	\$318
NPV						\$1.65
CytoSorb (Cardiac surgery EU)	1%	22.5%	0	70%	\$17	\$79
NPV						\$0.9
CytoSorb (Sepsis US)	1%	22.5%	4	50%	\$271	\$1,262
NPV						\$4.3
Net Margin						55%
MM Shrs OS (2030E)						35
Total						\$19

Source: Dawson James estimates

Risk Analysis

Market Share Risk: CytoSorbents' potential inability to further grow product sales in the EU will hinder its profitability as more capital is invested in clinical trials to bring CytoSorb to the U.S. market. The company's product represents a new treatment for critical care patients that may take longer for adoption than predicted.

Regulatory Risk: There may be certain regulatory risks related to CytoSorb approval in the U.S.

Commercial Risk: There is no guarantee that the company will be able to develop and expand sales operations to offset research and development costs. Delays in U.S. commercialization will be negatively reflected in its valuation.

Financial Risk: The company should be expected to raise capital in the near term. We assume a raise and dilution, but there is no guarantee that market conditions will be favorable.

Exhibit 9. Income Statement


CTSO.: Income Statement (\$'000)																								
:-YE December 31	1Q19A	2Q19A	3Q19A	4Q19A	2019A	1Q20A	2Q20E	3Q20E	4Q20E	2020E	1Q21E	2Q21E	3Q21E	4Q21E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Revenue:																								
CytoSorb Direct Sales (Germany, Austria, Switzerland)	4,576	5,850	5,728	6,612	22,766	5,050	5,160	5,590	5,805	21,500	9,255	9,657	10,462	10,865	40,239	54,439	69,046	84,070	99,520	115,405	131,735	148,520	150,699	150,699
CytoSorb Distributor (Rest of EU)	-	-	-	-	-	2,350	2,304	2,497	2,593	9,602	3,067	3,201	3,467	3,601	13,336	21,587	27,297	41,422	55,871	70,651	85,766	86,763	87,771	87,771
CytoSorb (Cardiac surgery EU)	-	-	-	-	-	710	720	780	810	3,000	1,579	1,648	1,785	1,854	6,866	9,218	11,604	14,022	16,474	16,589	16,705	16,822	16,940	16,940
CytoSorb (Cardiac surgery US)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16,294	21,899	27,593	66,755	67,290	67,829	68,373	68,373
CytoSorb (sepsis US)	-	-	-	-	-	-	-	-	-	-	2,018	2,106	2,281	2,369	8,773	17,846	45,376	92,302	187,755	200,508	223,353	246,919	271,225	271,225
VelResQ	-	-	-	-	-	45	36	39	41	150	36	38	41	43	158	165	174	182	191	-	-	-	-	-
Other Sales	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales	4,576	5,850	5,728	6,612	22,766	8,155	8,220	8,906	9,248	34,252	15,956	16,649	18,037	18,730	69,372	103,255	169,790	253,897	387,404	469,908	524,849	566,853	595,008	595,008
Royalty (HemoDefend US)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue	615	382	367	820	2,184	551	-	-	-	551	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	5,191	6,232	6,095	7,432	24,950	8,706	8,220	8,906	9,248	34,803	15,956	16,649	18,037	18,730	69,372	103,255	169,790	253,897	387,404	469,908	524,849	566,853	595,008	595,008
Expenses:																								
Costs of Goods Sold	1,738	1,834	1,696	2,096	7,364	2,385	1,644	1,781	1,850	7,660	3,191	3,330	3,607	3,746	13,874	20,651	33,958	50,779	77,481	93,982	104,970	113,371	119,002	119,002
	%COGS	38%	29%	25%	25%	29%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%	20%
Research and Development	2,418	2,930	3,185	3,559	12,092	1,965	3,192	3,458	3,591	13,301	3,365	3,512	3,804	3,950	14,631	16,094	17,704	19,474	21,422	23,564	25,920	28,512	31,364	34,500
	%R&D	53%	50%	56%	54%	24%	39%	39%	39%	39%	21%	21%	21%	21%	21%	16%	10%	8%	6%	5%	5%	5%	5%	6%
Selling, General and Administrative	4,758	4,506	6,108	6,634	22,006	6,317	6,074	6,580	6,833	25,307	6,694	6,985	7,567	7,858	29,103	32,013	32,653	33,307	33,973	34,852	35,345	36,052	36,773	37,509
	%SG&A	104%	77%	107%	100%	77%	74%	74%	74%	74%	42%	42%	42%	42%	42%	31%	19%	13%	9%	7%	7%	6%	6%	6%
Legal, financial and other counseling	561	592	733	576	2,462	519	591	640	665	2,462	566	591	640	665	2,462	2,462	2,462	2,462	2,462	2,462	2,462	2,462	2,462	2,462
Total Expenses	9,475	9,862	11,723	12,864	43,924	11,186	11,501	12,459	12,939	48,730	13,816	14,417	15,618	16,219	60,071	71,221	86,777	106,022	135,337	154,660	168,697	180,397	189,600	193,472
Operating Income (Loss)	(4,284)	(3,630)	(5,628)	(5,432)	(18,974)	(2,480)	(3,280)	(3,554)	(3,690)	(13,926)	2,139	2,232	2,418	2,511	9,301	32,034	83,013	147,875	252,067	315,248	356,152	386,456	405,408	401,536
Interest income (expense), net	(205)	(214)	(302)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) on foreign currency transactions	(393)	297	(956)	(332)	(1,384)	(668)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in warrant liability	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense), net	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Income	(598)	83	(1,258)	(332)	(1,384)	(974)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	(4,882)	(3,547)	(6,886)	(5,764)	(20,358)	(3,454)	(3,280)	(3,554)	(3,690)	(13,926)	2,139	2,232	2,418	2,511	9,301	32,034	83,013	147,875	252,067	315,248	356,152	386,456	405,408	401,536
Income Tax Benefit (Provision)	-	-	-	1,092	1,092	-	(262)	(284)	(295)	(1,114)	214	223	242	251	930	3,844	12,452	26,617	52,934	75,660	99,723	127,531	133,784	132,507
Tax Rate	0%	5%	5%	5%	5%	8%	8%	8%	8%	8%	10%	10%	10%	10%	10%	12%	15%	18%	21%	24%	28%	33%	33%	33%
GAAP Net Income (Loss)	(4,882)	(3,547)	(6,886)	(4,672)	(19,266)	(3,454)	(3,018)	(3,270)	(3,395)	(12,812)	1,925	2,009	2,176	2,260	8,371	28,190	70,561	121,257	199,133	239,589	256,429	258,926	271,623	269,029
GAAP-EPS	(0.15)	(0.11)	(0.21)	(0.14)	(0.60)	(0.10)	(0.09)	(0.10)	(0.10)	(0.38)	0.06	0.06	0.06	0.07	0.24	0.82	2.05	3.51	5.74	6.87	7.33	7.37	7.70	7.60
GAAP-EPS (Dil)	(0.15)	(0.11)	(0.21)	(0.14)	(0.60)	(0.10)	(0.09)	(0.10)	(0.10)	(0.38)	0.06	0.06	0.06	0.07	0.24	0.82	2.05	3.51	5.74	6.87	7.33	7.37	7.70	7.60
Wgtd Avg Shrs (Bas) - '000s	31,931	32,267	32,366	32,450	32,253	33,981	34,015	34,049	34,083	34,032	34,117	34,152	34,186	34,220	34,169	34,305	34,443	34,581	34,719	34,859	34,998	35,138	35,279	35,420
Wgtd Avg Shrs (Dil) - '000s	31,931	32,267	32,366	32,450	32,253	33,981	34,015	34,049	34,083	34,032	34,117	34,152	34,186	34,220	34,169	34,305	34,443	34,581	34,719	34,859	34,998	35,138	35,279	35,420

Source: Dawson James estimates

Important Disclosures:

Companies mentioned in this report include:

Price Chart:



Price target and rating changes over the past three years:

- Initiated – Buy – July 11, 2019 – Price Target \$15.00
- Update – Buy – August 12, 2019 – Price Target \$15.00
- Update – Buy – August 15, 2019 – Price Target \$15.00
- Update – Buy – August 19, 2019 – Price Target \$15.00
- Update – Buy – November 6, 2019 – Price Target \$15.00
- Update – Buy – February 19, 2020 – Price Target \$15.00
- Price Target Increase – Buy – March 9, 2020 – Price Target \$17.00
- Update – Buy – March 25, 2020 – Price Target \$17.00
- Update – Buy – April 13, 2020 – Price Target \$17.00
- Update – Buy – May 6, 2020 – Price Target \$17.00
- Update – Buy – June 9, 2020 – Price Target \$17.00

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with CTSO in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of May 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "STOCK VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	22	88%	3	14%
Market Perform (Neutral)	3	12%	1	33%
Market Underperform (Sell)	0	0%	0	0%
Total	25	100%	4	16%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.